{
    "id": 2695,
    "fullName": "ETV6 - NTRK3",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ETV6-NTRK3 results from the fusion of ETV6 and NTRK3, which leads to ligand-independent dimerization and activation of the fusion protein, transformation in cultured cells and tumor formation in animal models (PMID: 10702799). ETV6-NTRK3 fusions are associated with secretory breast carcinoma (PMID: 17425505).",
            "references": [
                {
                    "id": 1249,
                    "pubMedId": 10702799,
                    "title": "The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10702799"
                },
                {
                    "id": 11219,
                    "pubMedId": 17425505,
                    "title": "Recurrent fusion oncogenes in carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17425505"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2120,
        "geneSymbol": "ETV6",
        "terms": [
            "ETV6",
            "TEL",
            "TEL/ABL",
            "THC5"
        ]
    },
    "variant": "ETV6 - NTRK3",
    "createDate": "12/04/2014",
    "updateDate": "04/16/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4916,
                "geneSymbol": "NTRK3",
                "terms": [
                    "NTRK3",
                    "gp145(trkC)",
                    "GP145-TrkC",
                    "TRKC"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 14205,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in an objective response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 fusion (J Clin Oncol 36, 2018 (suppl; abstr 10536); NCT02650401).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3355,
                "name": "fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11509,
                    "pubMedId": null,
                    "title": "Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.",
                    "url": "https://meetinglibrary.asco.org/record/162773/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7378,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Rozlytrek (entrectinib) obtained through a Phase I trial resulted in a durable partial response in a patient with mammary analogue secretory carcinoma of the salivary gland harboring ETV6-NTRK3 (PMID: 26884591; NCT02097810).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8850,
                "name": "salivary gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3246,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) inhibited cell growth and downstream signaling in acute myeloid leukemia cells harboring ETV6-NTRK3 in culture and xenografts (PMID: 26216294).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3689,
                    "pubMedId": 26216294,
                    "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26216294"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15287,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a combined analysis of three trials, Vitrakvi (larotrectinib) treatment resulted in complete response in 21.4% (6/28) and partial response in 67.9% (19/28) of patients with advanced solid tumors harboring an ETV6-NTRK3 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14120,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring ETV6-NTRK3 was sensitive to treatment with Merestinib (LY2801653) compared to vehicle, demonstrating decreased tumor growth (PMID: 29568395).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11467,
                    "pubMedId": 29568395,
                    "title": "Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568395"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18728,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring ETV6-NTRK3 demonstrated a prolonged response when treated with PLX7486 (PMID: 31406350).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 2651,
                "therapyName": "PLX7486",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16327,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing ETV6-NTRK3 in culture (PMID: 30093503).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1421,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited ETV6-NTRK3 activity, reduced cell growth in a human acute myeloid leukemia cell line harboring ETV6-NTRK3, and had anti-tumor activity in xenograft models (PMID: 23811600).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1250,
                    "pubMedId": 23811600,
                    "title": "Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23811600"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3864,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing the fusion, ETV6-NTRK3, were treated with Lestaurtinib (CEP-701), which resulted in inhibition of ETV6-NTRK3 autophosphorylation and restoration of Tgf-b1 signaling (PMID: 16258068).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4250,
                    "pubMedId": 16258068,
                    "title": "The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16258068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3988,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "ETV6-NTRK3 fusions aid the diagnosis of congenital fibrosarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3975,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing ETV6-NTRK3 were sensitive to BMS-536924, demonstrating a reduction in both cell survival and transformation activity in culture (PMID: 21804605).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 683,
                "therapyName": "BMS-536924",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4256,
                    "pubMedId": 21804605,
                    "title": "A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21804605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15726,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation in culture (PMID: 26939704).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5130,
                    "pubMedId": 26939704,
                    "title": "Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26939704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11265,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 demonstrated tumor regression by 90% when treated with Vitrakvi (larotrectinib) (PMID: 28578312).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13813,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Vitrakvi (larotrectinib) treatment resulted in complete response in 33.3% (2/6) and partial response in 66.7% (4/6) of pediatric patients with congenital fibrosarcoma harboring ETV6-NTRK3 fusions (PMID: 29606586; NCT02637687).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11285,
                    "pubMedId": 29606586,
                    "title": "Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29606586"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7379,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with Vitrakvi (larotrectinib) resulted in a partial response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 (PMID: 27093299).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6328,
                    "pubMedId": 27093299,
                    "title": "Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27093299"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16266,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH7057288 inhibited NTRK phosphorylation and downstream signaling and reduced growth of acute myeloid leukemia cells harboring ETV6-NTRK3 in culture, and induced tumor regression in xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 7977,
                "therapyName": "CH7057288",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7380,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ETV6-NTRK3 demonstrated sensitivity to Altiratinib (DCC-2701) in culture, resulting in inhibition of Ntrk3 phosphorylation and decreased cell proliferation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 790).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6329,
                    "pubMedId": null,
                    "title": "Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/790.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1567,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the broad spectrum kinase inhibitor midostaurin inhibited growth of cells dependent on the fusion protein ETV6-NTRK3, reducing ETV6-NTRK3 kinase activity and downstream signaling and inducing apoptosis (PMID: 23131561).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1543,
                    "pubMedId": 23131561,
                    "title": "ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23131561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15727,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in a brief stable disease in a patient with mammary analogue secretory carcinoma of the salivary gland harboring ETV6-NTRK3, before disease progression at 18 weeks (PMID: 26884591).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8850,
                "name": "salivary gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-6051a inhibited MAPK, PI3K, and PLCgamma-1 signaling in transformed melanocytes expressing ETV6-NTRK3 in culture (PMID: 27477320).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 6869,
                "therapyName": "DS-6051a",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11065,
                    "pubMedId": 27477320,
                    "title": "NTRK3 kinase fusions in Spitz tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27477320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14361,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in complete response in 1 and partial response in 2 patients with gastrointestinal stromal tumor harboring ETV6-NTRK3 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                },
                {
                    "id": 11608,
                    "pubMedId": null,
                    "title": "Activity of larotrectinib in patients with TRK fusion GI malignancies",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy149.019/5039356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2500,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-754807 inhibited tumor growth in cell line xenograft models of breast cancer cells overexpressing ETV6-NTRK3 (PMID: 21148487).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3183,
                    "pubMedId": 21148487,
                    "title": "ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21148487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12708,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Rozlytrek (entrectinib) treatment resulted in rapid response and tumor necrosis in a patient with a small intestine neuroendocrine tumor harboring a ETV6-NTRK3 fusion (PMID: 29118225; NCT02568267).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 4434,
                "name": "small intestine neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10619,
                    "pubMedId": 29118225,
                    "title": "Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29118225"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15275,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, NTRK3 G623R was identified at disease progression in a pediatric patient with IFS (infantile fibrosarcoma and GIST gastrointestinal stromal tumor) harboring ETV6-NTRK3 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3520,
                "name": "pediatric fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16328,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 in culture (PMID: 30093503).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 demonstrated resistance to Xalkori (crizotinib) relative to ETV6-NTRK3 expressing cells in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15730,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 demonstrated resistance to Vitrakvi (larotrectinib) relative to ETV6-NTRK3 expressing cells in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11268,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 and NTRK3 G623R demonstrated a partial response after 28 days when treated with LOXO-195, which continued after 66 days, however, after an additional month progression ensued (PMID: 28578312).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 demonstrated resistance to Belizatinib (TSR-011) relative to ETV6-NTRK3 expressing cells in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 949,
                "therapyName": "Belizatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15714,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with mammary analogue secretory carcinoma of the salivary gland harboring ETV6-NTRK3 initially responded to Rozlytrek (entrectinib) obtained through a Phase I trial, but her disease progressed and NTRK3 G623R was identified as an acquired mutation at disease progression (PMID: 26884591; NCT02097810).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8850,
                "name": "salivary gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11266,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 progressed on treatment with Vitrakvi (larotrectinib) after 8 months and was found to have acquired NTRK3 G623R (PMID: 28578312).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15274,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK3 G696A and NTRK3 G623R were identified at disease progression in a patient with a gastrointestinal stromal tumor harboring ETV6-NTRK3 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30936,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R NTRK3 G696A"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16332,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Repotrectinib (TPX-0005) treatment resulted in partial response and tumor shrinkage in a patient with mammary analogue secretory carcinoma of the parotid gland harboring NTRK3 G623E in the context of ETV6-NTRK3, and the patient remained on treatment for over 17 months (PMID: 30093503; NCT03093116).",
            "molecularProfile": {
                "id": 31603,
                "profileName": "ETV6 - NTRK3 NTRK3 G623E"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9036,
                "name": "parotid gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16331,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with mammary analogue secretory carcinoma of the parotid gland harboring an ETV6-NTRK3 fusion developed progressive disease after initial response to Rozlytrek (entrectinib), and NTRK3 G623E was identified in the post-progression biopsy (PMID: 30093503).",
            "molecularProfile": {
                "id": 31603,
                "profileName": "ETV6 - NTRK3 NTRK3 G623E"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9036,
                "name": "parotid gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16329,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing NTRK3 G623E in the context of ETV6-NTRK3 in culture (PMID: 30093503).",
            "molecularProfile": {
                "id": 31603,
                "profileName": "ETV6 - NTRK3 NTRK3 G623E"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18731,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a secondary resistance mutation, MAP2K1 P124S, was identified via cell-free DNA testing after a patient with pancreatic cancer harboring ETV6-NTRK3 progressed on LOXO-195 treatment (PMID: 31406350).",
            "molecularProfile": {
                "id": 33528,
                "profileName": "ETV6 - NTRK3 MAP2K1 P124S"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2514,
            "profileName": "ETV6 - NTRK3",
            "profileTreatmentApproaches": [
                {
                    "id": 19330,
                    "name": "Larotrectinib",
                    "profileName": "ETV6 - NTRK3"
                },
                {
                    "id": 6916,
                    "name": "Trk Receptor Inhibitor (Pan)",
                    "profileName": "ETV6 - NTRK3"
                },
                {
                    "id": 6917,
                    "name": "Crizotinib",
                    "profileName": "ETV6 - NTRK3"
                },
                {
                    "id": 7313,
                    "name": "IGF-1R Inhibitor",
                    "profileName": "ETV6 - NTRK3"
                }
            ]
        },
        {
            "id": 27941,
            "profileName": "ETV6 - NTRK3 NTRK3 G623R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30936,
            "profileName": "ETV6 - NTRK3 NTRK3 G623R NTRK3 G696A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31603,
            "profileName": "ETV6 - NTRK3 NTRK3 G623E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33528,
            "profileName": "ETV6 - NTRK3 MAP2K1 P124S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}